Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$70.37 USD

70.37
1,742,354

+0.14 (0.20%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $70.37 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Ecolab (ECL) to Report Q3 Earnings: Will It Disappoint?

Ecolab's (ECL) large base of recurring revenues, industry-leading technologies and excellent field service are propellers. However, the company faces cut-throat competition in the niche space.

    Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?

    Myriad Genetics (MYGN) is positioned to deliver solid results in Q1 on the back of the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.

      What's in Store for Cardinal Health (CAH) in Q1 Earnings?

      Cardinal Health (CAH), a global player in the healthcare services and products space, has been grappling with pricing deflation in the generics segment in the first quarter.

        Henry Schein (HSIC) Q3 Earnings to Show Growth in All Lines

        Henry Schein (HSIC) likely to gain on strength across all business segments in Q3.

          Will Higher System Sales Drive Cerner's (CERN) Q3 Earnings?

          Strong growth in licensed software and subscriptions are expected to be the main factors driving systems revenues for Cerner (CERN) in the third quarter of 2017.

            Will Sage-Unit Recall Hurt Stryker's (SYK) Q3 Earnings?

            In August, Stryker (SYK) announced a voluntary recall of the Oral Care line-up, which was offered by the company's Sage-Products unit.

              Mckesson (MCK) to Report Q2 Earnings: A Beat in the Cards?

              McKesson Corporation (MCK) expects a strong second quarter owing to a gradually stabilizing generic and branded market.

                What's in the Cards for LabCorp (LH) This Earnings Season?

                LabCorp (LH) might gain from continued growth in its companion diagnostics portfolio in Q3.

                  Will GNC Holdings (GNC) Disappoint This Earnings Season?

                  Revenue growth at GNC Holdings (GNC) might remain sluggish on declining sales of protein, vitamins, weight management and food and drink categories in Q3.

                    Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?

                    We are upbeat about Varian Medical's oncology business that accounted for around 95% of the company's total revenue in fourth-quarter 2017.

                      Baxter International (BAX) Q3 Earnings: What's in Store?

                      Baxter International Inc's (BAX) third quarter estimate revision trend is encouraging due to acquisitions and strategic collaborations to enhance its product portfolio.

                        Walgreens Boots (WBA) to Report Q4 Earnings: What's in Store?

                        Walgreens Boots (WBA) may witness another quarter of prescription growth and strength in Retail Pharmacy USA division in Q4 earnings.

                          Can Illumina (ILMN) Maintain Balanced Growth in Q3 Earnings?

                          Illumina (ILMN) might gain from continued growth in Product as well as Service and other segments in the third quarter.

                            Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?

                            Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.

                              Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?

                              Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.

                                Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?

                                Nutrisystem's (NTRI) innovative products are expected to expand customer base that will eventually drive reactivation revenues in Q3.

                                  What to Expect From Thermo Fisher (TMO) in Q3 Earnings

                                  Thermo Fisher (TMO) gears up for another quarter of strong analytical instruments segmental growth. Improvement is likely to be seen in applied markets too.

                                    Henry Schein (HSIC) Inks Distribution Agreement with Terason

                                    Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.

                                      Will PBM Slowdown Hamper Express Scripts (ESRX) Q3 Earnings?

                                      Lackluster performance in PBM product network and services segment is likely to mar Express Scripts' (ESRX) revenues in the third quarter.

                                        Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings?

                                        We believe that the growing adoption of Intuitive Surgical's (ISRG) da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the quarter.

                                          Can CR Bard (BCR) Spring a Surprise This Earnings Season?

                                          We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon will result in improved performance for CR Bard (BCR) in Q3.

                                            Here's Why Investors Should Sell Patterson Companies Now

                                            Rapidly changing healthcare environment in the United States, unfavorable price movement, a competitive dental products distribution industry and integration risks pose significant challenges for Patterson Companies (PDCO).

                                              Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?

                                              ResMed (RMD) may ride high in Q1 on continued growth in its domestic as well as overseas business.

                                                Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe

                                                Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.

                                                  Henry Schein Closes Merritt Buyout, Expands in Animal Health

                                                  Henry Schein (HSIC) is consistently trying to expand its Animal Health business.